Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV

Zhenyan Wang; Junyang Yang; Lin Wang; Jiangrong Wang; Yinzhong Shen; Jun Chen; Tangkai Qi; Jianjun Sun; Wei Song; Yang Tang; Shuibao Xu; Li Liu; Renfang Zhang

doi:10.1186/s12981-024-00680-x

AIDS Research and Therapy (Nov 2024)

Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV

Zhenyan Wang,
Junyang Yang,
Lin Wang,
Jiangrong Wang,
Yinzhong Shen,
Jun Chen,
Tangkai Qi,
Jianjun Sun,
Wei Song,
Yang Tang,
Shuibao Xu,
Li Liu,
Renfang Zhang

Affiliations

Zhenyan Wang: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University
Junyang Yang: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University
Lin Wang: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University
Jiangrong Wang: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University
Yinzhong Shen: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University
Jun Chen: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University
Tangkai Qi: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University
Jianjun Sun: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University
Wei Song: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University
Yang Tang: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University
Shuibao Xu: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University
Li Liu: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University
Renfang Zhang: Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University

DOI: https://doi.org/10.1186/s12981-024-00680-x
Journal volume & issue: Vol. 21, no. 1
pp. 1 – 5

Abstract

Read online

Abstract This study aimed to evaluate the efficacy and safety of dolutegravir plus lamivudine (DTG/3TC) in antiretroviral treatment (ART)-experienced people living with HIV (PLWH). A total of 303 PLWH in Shanghai, China, who switched from triple ART to DTG/3TC between January 2019 and June 2022, with a minimum ART duration of 6 months, were retrospectively enrolled. More than 95% of PLWH maintained viral suppression with no significant changes in CD4 counts 12 months after switching. Patients transitioning from non-tenofovir (TDF)-based regimens demonstrated more pronounced improvements in lipid profiles, while those previously on TDF-based regimens showed greater enhancements in bone metabolism.

Published in AIDS Research and Therapy

ISSN: 1742-6405 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://aidsrestherapy.biomedcentral.com

About the journal

Abstract

Keywords